Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease

Gurumurthy, Prema and Ramachandran, Geetha and Hemanth Kumar, A K and Rajasekaran, S and Padmapriyadarshini, C and Swaminathan, Soumya and Bhagavathy, S and Venkatesan, P and Sekar, L and Mahilmaran, A and Ravichandran, N and Paramesh, P (2004) Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease. Antimicrobial Agents and Chemotherapy, 48 (11). pp. 4473-4475. ISSN Print: 0066-4804; Online: 1098-6596

Preview

PDF 200428.pdf - Published Version Download (44kB)

Abstract

We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine. Peak concentration and exposure were reduced for rifampin, and rapid acetylators of isoniazid had lower drug levels. HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs.

Actions (login required)

View Item